- MEDIUM
- Business
- Tier 1
- Hard News
vVardis launches US IPO at $18 per share
- Source
- Becker's Dental + DSO Review
- Author
- Cameron Cortigiano
- Originally at
- beckersdental.com(opens in a new tab)
Summary and scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol. Not the original publisher.
Why it matters for dental
Practice owners and DSOs gain visibility into a vendor that has already placed its Curodont line in more than 20,000 U.S. dental practices, which may affect future purchasing decisions, supplier stability, and competitive positioning.
Key points
- 01
vVardis, a Zug, Switzerland-based dental medical technology company, launched a U.S. IPO priced at $18 per share.
- 02
The offering consists of 9,722,223 Class A ordinary shares and raised $175 million ahead of the IPO.
- 03
vVardis filed for the IPO in October and targeted a $4.37 billion valuation.
- 04
Curodont products, sold to more than 20,000 U.S. dental practices, are expected to begin trading on the New York Stock Exchange on.
Who should care
- Owner
- DSO
Read the original
Becker's Dental + DSO Review
Full reporting and any paywalled content live on beckersdental.com. We summarize and score; we do not republish.